‘Sing Sing’ screens at Sing Sing, in an emotional homecoming for its cast

By Jake Coyle, The Associated Press

OSSINING, N.Y. (AP) — Clarence “Divine Eye” Maclin is standing inside Sing Sing Correctional Facility for the first time since he was incarcerated here 12 years ago. In this very chapel, he reminisces, he once sold drugs — a backup plan for when the yard was closed.

Not many men pine to return to the prisons in which they toiled away years of their life. Maclin, 58, lived inside Sing Sing for 15 years. But on this day, he’s buoyant.

“I got a purpose now,” Maclin says.

Maclin was at Sing Sing, the 198-year-old maximum-security prison perched on a hillside overlooking the Hudson 30 miles upriver from New York City, last Thursday for the premiere of the upcoming movie “Sing Sing.” In the film, which opens July 12 in theaters, Colman Domingo stars as an incarcerated man who helps lead a theater program for others at Sing Sing. Together, they find community and catharsis through theater.

The program is real: Rehabilitation Through the Arts, or RTA, is a nonprofit founded by Katherine Vockins at Sing Sing in 1996. Many of its former participants make up the cast of “Sing Sing” alongside professional actors like Domingo and Paul Raci. Maclin plays himself – a hard, muscle-bound character whose talent for shake-downs in the yard, it turns out, transfers remarkably well to Shakespeare.

“On stage,” Maclin says, “I got permission to do anything.”

As movie premieres go, the one for “Sing Sing” at Sing Sing was about as poignant as it gets. The film was screened above the stage where RTA performed its first show for an audience half civilian, half incarcerated men in navy green jumpsuits. For the formerly incarcerated actors in the film, returning to Sing Sing was an emotional homecoming. They brought a message of hope and healing that they, themselves, are still trying to live up to.

Plaques outside the walls of Sing Sing — a high-walled citadel of incarceration beside which trains carrying commuters pass regularly — tout its rich history. This is where phrases long ubiquitous in movies — “Up the river,” “the Big House” — come from. Historically, Sing Sing — where, among many others, Julius and Ethel Rosenberg were executed — has loomed in the public imagination more as a symbol of harsh, Victorian age-style punishment than soulful rehabilitation.

On a sweltering day with the sun still high above the Hudson, two former RTA members — Lorenzo Chambers, 33, and Jose Robles, 64 — stood outside the prison walls, handing out water bottles. In his 35-plus years in prison, Robles first began building sets for RTA productions and then became a performer.

“You learn more about yourself than you do the play, you know?” says Robles.

Inside the first gate, Sean Dino Johnson, a founding member of RTA and a co-star in “Sing Sing,” sits in the shade, cringing a little each time the gate opened and closed. Johnson, 59, served 22 years in prison. When he was first approached about RTA nearly two decades ago, he was a tad skeptical.

“I said, ‘You want me to get up there in tights and do ‘To be or not to be’?” recalls Johnson, grinning. “Where’s the punchline at?”

But Johnson, despite his doubts, gave it a go and soon found that he had “got the bug.” Looking inward as an actor brought him an inner peace that had previously eluded him.

“That was my first understanding of what a community is,” says Johnson as he makes his way up the hill to the theater.

___

While the cast members and others mill about in the chapel, the film’s director and co-writer, Greg Kwedar, eyes the next-door theater nervously. “Sing Sing” was largely shot at a decommissioned prison upstate, so this was a moment he had long awaited.

“I’ve imagined what this theater would look like for eight years,” Kwedar says. “This is the most important audience in the world for us. I just hope it’s honest.”

“When we walk out of here, I hope the air feels a little different for those of us who are going home,” adds Kwedar. “And I’m highly aware that half of the audience will be going back to their cells.”

Since its debut at the Toronto International Film Festival, “Sing Sing” has been widely celebrated. A24 acquired it soon after its premiere. In March, it won the festival favorite audience award at SXSW.

The emotional response “Sing Sing” provokes runs two ways, eradicating some of the divisions that exist between those on the inside and those on the outside. For the RTA alumni, it’s a rare platform to show that what they’re capable of. For civilians less acquainted with the oft-ignored lives of the incarcerated, it’s a window into their humanity.

“You don’t feel as separated from the world,” says Shaytuan Breazil, a 32-year-old serving a 12-year sentence who was helping to serve snacks for visitors.

When RTA started, performances were only for fellow incarcerated men. Its leaders, like director Brent Buell (played by Raci in the film), would make videotapes for their families to see. What began with modest expectations grew and grew. “I thought I’d come up here and direct — I love directing,” says Buell. “I had no idea I would come in and make the friendships of my life.”

More than 1,000 people have since passed through RTA, which is now in eight prison facilities. It plans to expand to two more in September. The U.S. Department of Justice has found that within one year of release, 43% of formerly incarcerated people are rearrested. Among RTA alumni, that number is less than 3%.

Jon-Adrian “JJ” Velazquez served more than 23 years in Sing Sing before he was granted clemency for his wrongful conviction by former New York Gov. Andrew Cuomo. He has worked closely with RTA and appears in “Sing Sing.”

“The most effective way to change somebody,” says Velazquez, “is to believe in them.”

___

Inside the un-air conditioned theater, old stained glass windows had been blacked out. Guards sat in elevated chairs along the walls. The former incarcerated men warmly greeted those currently serving across the aisle. It was the third screening that day at Sing Sing, whose warden, Marlyn Kopp, said she wanted the whole population to see it. (The first two screenings were for incarcerated people only.)

After sitting in a row toward the back, Maclin was urged to take a seat in the front row. “I’m moving up,” he says as he bounded to the front. There were old acquaintances Maclin wanted to see at Sing Sing but, he said before the screening, it was more important that the incarcerated men saw him, to realize what life after prison could hold.

When the movie was over, the incarcerated audience appeared visibly moved and stood in a standing ovation. They stood again just to applaud A24. Their biggest cheers weren’t for Domingo but those who had been jailed alongside them. After the film, Maclin and Johnson spoke on stage with a pair of currently incarcerated men who shared their emotional reaction.

“I’m home,” Maclin said. “Back home on my stage.”

Maclin and Johnson faced their chairs toward those incarcerated and addressed most of their comments directly to them. Whatever one might think normally is discussed inside prison walls would be startled at the tenor of the conversation. Acting, Maclin said, taught him that vulnerability and empathy weren’t weaknesses but strengths. Johnson spoke of listening, the importance of crying and of love. Keep working, he implored. “Men can change,” he said.

Soon, curfew would be called and the men of B Block would file out first. But for now, many heads nodded in agreement at Johnson’s words. They didn’t have much, Johnson told them, but they have each other. And for RTA members when they get out, alums would be there with a ride, some help and maybe a few dollars for their pocket.

“This was Sing Sing’s best kept secret,” said Johnson. “Now, the world’s gonna know.”

___

Follow AP Film Writer Jake Coyle at: http://x.com/jakecoyleAP

Jake Coyle, The Associated Press








Keep it Factual
Add CityNews Toronto as a trusted source on Google to see more local stories from us.

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

4h ago

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

4h ago

Most Watched Today